This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Are Kimberly-Clark and Procter & Gamble Worth Buying Now?

NEW YORK (TheStreet) -- NEW YORK (TheStreet) -- Among consumer staple stocks, two investor favorites are Kimberly-Clark (KMB) and Procter & Gamble (PG). Both are priced with hefty forward one-year price-to-earnings ratios between 16.5 and 18, and both face challenging headwinds.

As of 3:30 p.m. on Tuesday, Kimberley-Clark stock was at $108.50, up 4% year to date. Procter & Gamble was at $81.42, down 0.1% year to date.

Kimberly-Clark reported first-quarter 2014 earnings on Monday, April 21, with earnings per share of $1.48. That was slightly better than the $1.47 analysts were expecting, according to Yahoo! Finance.

The same groups of analysts anticipated quarterly revenue of $5.32 billion. The actual number was $5.3 billion, a 1% decrease compared to the year-ago period. As the following 12-month chart clearly demonstrates, shares of Kimberly-Clark have performed well.

KMB Chart

KMB data by YCharts

Since the Oct. 8, 2013, low of $93.12 to the 52-week high last Friday of $113.09, shares of Kimberly-Clark had a remarkable run-up of over 21%. Now the shares are experiencing a well-deserved correction.

The company's amazing revenue-per-share growth may have topped out for the time being. On Tuesday, April 22, shares of Kimberly-Clark fell below the 50-day exponential moving average. This offers an auspicious chance to begin accumulating if you don't own the stock.

The next important support level is the 200-day exponential moving average of $104.34. It makes sense to be patient and average down on purchases of Kimberly-Clark.

The key financial number that concerns me is Kimberly-Clark's cash generated by operations in the first quarter of 2014, which was $437 million, compared to $607 million in 2013. Higher pension contributions and increased working capital costs were the reasons given by company management.

Investors need to make sure the company's free cash flow is enough to support its generous $3.36 annual dividend. At a share price of $109, that offers a yield of 3.08%. The 60% payout ratio may limit how much the company increases the dividend this year.

Besides it profitable businesses and dividend, one big reason for Kimberley-Clark's share price performance is the promise of a pending spinoff. Last November the company announced plans for a tax-free spin-off of its health care business. The proposed spinoff would create a stand-alone, publicly traded health care company with approximately $1.6 billion in annual net sales in both surgical and infection-prevention products and medical devices.

The spinoff is expected to be completed by the end of the third quarter or sometime in the fourth quarter of 2014, assuming board approval and subject to market, regulatory and other conditions.

Looking ahead, Kimberly-Clark's management guided for earnings-per-share growth in 2014 between 4% and 7%, but revenue may only increase by less than 3%. That may put a lid on the upside target price, which I calculate to be about $116.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,156.85 +24.88 0.15%
S&P 500 2,001.57 +2.59 0.13%
NASDAQ 4,562.1890 +9.43 0.21%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs